Global Market Direct's Endologix, Inc. - Medical Equipment - Deals and Alliances Profile is an essential source for company data and information. The profile examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy as well as highlighting the company's major recent financial deals.
Endologix, Inc. (Endologix) develops, manufactures and sells minimally invasive treatments for vascular diseases. The company is focusing on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). AAA is a weakening of the wall of the aorta which is the largest artery of the body. Endologix markets its Powerlink Delivery System an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA that has certain advantages when compared to marketed stent alternatives. The company received FDA approval for the Powerlink AAA stent graft in 2004. The Powerlink superior design is covered by 17 US patents with 361 allowed claims.And More inside the report...
This report covers the following industry codes:
SIC Code: 3841
NAICS Code: 332994
Endologix, Inc. (Endologix) is a medical device company engaged in developing, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). Its Powerlink Delivery System is an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA; and has certain advantages when compared to marketed stent alternatives. The Powerlink superior design is covered by 17 US issued patents with 361 claims. The device is available in the US and selected international markets. The company is headquartered in California, the US.
Endologix, Inc. Key Recent Developments
Oct 27, 2011: Endologix Reports Revenues Of $22.3m In Q3 2011
Aug 30, 2011: Endologix Appoints Ruth Lyons As Vice President, Global Marketing
Aug 18, 2011: Cook Medical Remains Resolute In Pursuit Of Infringement Action Against Endologix Following Markman Ruling
Aug 17, 2011: Endologix Announces Favorable Markman Ruling In Cook Patent Litigation
Jul 21, 2011: Endologix Reports Total Revenue Of $19.2m In Q2 2011
This comprehensive SWOT profile of Endologix, Inc. provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Note: Some sections may be missing if data is unavailable for the company.
You get detailed information about the company and its operations to identify potential customers and suppliers.
Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Gain key insights into the company for academic or business research.
Endologix, Inc. (ELGX) - Product Pipeline Analysis
Endologix, Inc. (Endologix) is a medical device company engaged in developing, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). Its Powerlink Delivery System is an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA; and has certain advantages when compared to marketed stent alternatives. The Powerlink superior design is covered by 17 US issued patents with 361 claims. The device is available in the US and selected international markets. The company is headquartered in California, the US.
This report is a source for data, analysis and actionable intelligence on the Endologix, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.
Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
This report covers the following industry codes:
SIC Code: 3841
NAICS Code: 332994
Endologix, Inc. (Endologix) is a medical device company engaged in developing, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). Its Powerlink Delivery System is an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA; and has certain advantages when compared to marketed stent alternatives. The Powerlink superior design is covered by 17 US issued patents with 361 claims. The device is available in the US and selected international markets. The company is headquartered in California, the US.
Endologix, Inc. (ELGX) - Medical Equipment - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company's mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.
Data presented in this report was derived from GlobalData's proprietary in-house Medical Equipment eTrack deals database and primary and secondary research.
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements.
Understand the company's business segments' expansion / divesture strategy
Access detailed information about the company's recent financial deals that enables you to understand the key deals which have shaped the company
Equip yourself with detailed information about the company to identify potential customers and suppliers.